Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to sift through pages of clinical jargon just to see how LINZESS sales or IBS-C trial costs impact Ironwood Pharmaceuticals? Biopharma filings can bury crucial details on royalty rates, FDA milestones, and pipeline spend. That’s why Stock Titan places every Ironwood Pharmaceuticals SEC filing in one organised hub and layers it with AI-powered summaries that translate complex disclosures into plain language.
Want the latest numbers? Our system pulls the Ironwood Pharmaceuticals quarterly earnings report 10-Q filing the moment it hits EDGAR. Curious about leadership moves? We stream Ironwood Pharmaceuticals Form 4 insider transactions real-time, so you can monitor executive stock activity alongside LINZESS performance. Each document—whether a 10-K annual report, 8-K clinical update, or DEF 14A proxy—is paired with concise explanations that answer everyday questions like “How is Ironwood funding its Phase III GI program?” or “What does the latest 8-K material event mean for revenue guidance?”
Here’s what you’ll uncover faster than ever:
- Ironwood Pharmaceuticals annual report 10-K simplified to reveal GI market share, royalty waterfalls, and risk factors.
- Ironwood Pharmaceuticals insider trading Form 4 transactions and alerts on option exercises.
- Board and pay insights inside the Ironwood Pharmaceuticals proxy statement executive compensation filing.
- Instant context for every Ironwood Pharmaceuticals 8-K material events explained by AI.
- Side-by-side Ironwood Pharmaceuticals earnings report filing analysis that tracks R&D burn against pipeline milestones.
Stop guessing and start understanding Ironwood Pharmaceuticals SEC documents with AI. Stock Titan’s expert engine converts dense biotech paperwork into clear takeaways—so you can focus on decisions, not decoding.
enGene Holdings Inc. (ENGN) – Form 4 filing dated 10 July 2025
The filing discloses a routine equity compensation grant to new director Michael Thomas Heffernan. On 08 July 2025 the company issued a stock option to purchase 45,000 common shares at an exercise price of $3.83 per share. The option expires on 08 July 2035 and vests in three equal annual tranches (one-third on each of the first, second and third anniversaries of Mr. Heffernan’s board appointment on 08 July 2025). After the grant, Mr. Heffernan beneficially owns 45,000 derivative securities, held directly. No common shares were bought or sold, and no cash changed hands at this stage; the transaction represents potential future dilution only if the options are exercised.
- Form type: Form 4 (Section 16 insider transaction)
- Reporting person’s role: Director (not an officer or 10% owner)
- Nature of transaction: Initial option grant – Code “A” (acquisition)
- Potential value: Intrinsic value depends on future share price exceeding $3.83
The grant aligns director incentives with shareholder performance but is immaterial to the company’s overall share count and financials.
Schedule 13G Overview – The Vanguard Group & Ralliant Corp (RAL)
On 30 June 2025, The Vanguard Group filed a Schedule 13G reporting passive beneficial ownership of Ralliant Corp’s common stock. Vanguard now controls 13,174,096 shares, representing 11.65 % of RAL’s outstanding shares. The filing is made under Rule 13d-1(b) because Vanguard is an SEC-registered investment adviser ("IA").
Voting vs. dispositive authority
- Sole voting power: 0 shares
- Shared voting power: 49,118 shares
- Sole dispositive power: 12,898,650 shares
- Shared dispositive power: 275,446 shares
While Vanguard has virtually no direct voting power, it retains the right to dispose of nearly all of the reported shares, indicating the holding is spread across indexed and managed funds that delegate voting to third parties or follow fund-level policies.
Implications for investors
- Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially increasing RAL’s visibility among passive and ETF-tracking investors.
- The passive 13G filing (rather than an activist 13D) signals no intention to influence control or strategy.
- Concentrated ownership may add liquidity support but could create share-supply risk if Vanguard trims its position.
The certification confirms the stake was acquired in the ordinary course of business and not to influence management. The document is signed by Ashley Grim, Head of Global Fund Administration, on 7 July 2025.
FAQ
What is the current stock price of Ironwood (IRWD)?
What is the market cap of Ironwood (IRWD)?
What is Ironwood Pharmaceuticals' primary focus?
How does Ironwood generate revenue?
What distinguishes Ironwood in the competitive biopharmaceutical landscape?
What are the key therapeutic areas addressed by the company?
How does Ironwood approach research and development?
How does the company maintain its scientific and clinical expertise?
How does Ironwood differentiate its pipeline from competitors?
What are the core operational strategies of Ironwood Pharmaceuticals?
